Defendant Name: Nano-x Imaging Ltd.

Defendant Type: Public Company
SIC Code: 9999
CUSIP: M7070010

Initial Case Details

Legal Case Name Nano-X Imaging Ltd.
First Document Date 29-Sep-2023
Initial Filing Format Civil Proceeding
Case Number 23-cv-08611
Allegation Type Issuer Reporting and Disclosure
Federal District Court New York, Southern District of New York

Violations Alleged

Exchange Act
• Rule 12b-20
• Sec 13(a)
• Rule 13a-1
Securities Act
• Sec 17(a)(2)
Additionally, Ran Poliakine is alleged to have aided and abetted Nano-x Imaging Ltd. 's violation of Rule 12b-20 of the Exchange Act.
Ran Poliakine is alleged to have aided and abetted Nano-x Imaging Ltd. 's violation of Sec 13(a) of the Exchange Act.
Ran Poliakine is alleged to have aided and abetted Nano-x Imaging Ltd. 's violation of Rule 13a-1 of the Exchange Act.

Resolutions

First Resolution Date 29-Sep-2023

Related Documents:

comp25876 29-Sep-2023 Complaint
Complaint
The SEC alleged "From August 2020 through May 2021, Nanox, an Israel-based medical imaging company, and Poliakine, its founder and then CEO, negligently made a series of false and misleading statements to investors about the estimated cost to manufacture at least 15,000 units of its flagship product, the Nanox.ARC - a device the company is developing that it claimed would make diagnostic imaging substantially more affordable than currently available medical imaging systems and accessible to patients around the globe."
LR-25876 29-Sep-2023 Litigation Release
SEC Charges Diagnostic Imaging Company and Its Former CEO for Misrepresenting the Manufacturing Costs of Its Flagship Device
On September 29, 2023, the SEC "announced charges against an Israel-based diagnostic imaging company, Nano-X Imaging Ltd. (“Nanox”), and its former CEO, Ran Poliakine (“Poliakine”), for negligently misrepresenting the cost to manufacture the company’s flagship imaging device, the Nanox.ARC. Nanox and Poliakine have agreed to settle the SEC’s charges."

Other Defendants in Action:

Ran Poliakine